Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …

With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …

Abstract Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however,
an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe …

Background Given the scale of the ongoing COVID-19 pandemic, the development of
vaccines based on different platforms is essential, particularly in light of emerging viral …

The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a …

The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the
continued development of novel improved formulations capable of reducing the burden of …

Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world
has vehemently worked to develop treatments and vaccines against severe acute …

In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from
patients with severe pneumonic disease in China. This virus is closely related to Mòjiāng …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than
160 million people and resulted in more than 3.3 million deaths, and despite the availability …

Recombinant protein approaches offer major promise for safe and effective vaccine
prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine …